Affinage

HDAC11

Histone deacetylase 11 · UniProt Q96DB2

Length
347 aa
Mass
39.2 kDa
Annotated
2026-06-10
93 papers in source corpus 32 papers cited in narrative 32 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 4/4 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

HDAC11 is the sole class IV histone deacetylase, an enzyme whose dominant biochemical activity is highly efficient lysine defatty-acylation (>10,000-fold more active than its canonical deacetylase function) and which acts as a multifunctional eraser of lysine acylation on both metabolic/signaling proteins and chromatin (PMID:11948178, PMID:30819897). Through its catalytic activity it removes fatty-acyl and acetyl marks from a growing set of non-histone substrates with distinct functional consequences: defatty-acylation of SHMT2 suppresses type I IFN receptor levels and signaling (PMID:30819897), demyristoylation of gravin-α/AKAP12 restrains β-adrenergic/UCP1-driven thermogenesis (PMID:37607030), deacetylation of BRAF K680 suppresses kinase activity and proliferation (PMID:41273269), deacetylation of TPI1 K69 stabilizes the protein against ubiquitination to promote myofibroblast differentiation (PMID:41112094), and deacetylation of Parkin K76 promotes its degradation to impair mitophagy (PMID:41997918). In parallel, HDAC11 functions as a chromatin-associated transcriptional repressor, being recruited to specific gene promoters where it lowers histone acetylation — repressing IL-10 in antigen-presenting cells (PMID:19011628), Eomes/Tbet to restrain T-cell effector function (PMID:28550044), Nos2 via STAT3 scaffolding (PMID:36087429), and the myogenic program in a catalytic-activity-dependent manner (PMID:28927261). It carries out these promoter functions within or alongside protein complexes including HDAC6 (PMID:11948178, PMID:24747960), BRD2 (PMID:30089714), and the NuRD(MTA3) complex through its N-terminal region (PMID:41547814), and its abundance is controlled by ubiquitin-dependent turnover regulated by USP25 and March1 (PMID:31746627, PMID:34385821). Collectively, HDAC11 links lysine acylation/deacylation chemistry to immune tolerance, thermogenesis and metabolism, fibrosis, and viral and transcriptional control.

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 2002 High

    Established HDAC11 as a catalytically active, complex-forming deacetylase, defining the founding biochemical identity of the enzyme.

    Evidence In vitro deacetylase assay with trapoxin inhibition and Co-IP with HDAC6, nuclear localization by epitope tagging

    PMID:11948178

    Open questions at the time
    • Physiological substrates not identified
    • Functional consequence of HDAC6 association unresolved
  2. 2008 High

    Showed HDAC11 is a promoter-associated transcriptional repressor with an immune function, repressing IL-10 to shape APC inflammatory phenotype and immune tolerance.

    Evidence Reciprocal overexpression/siRNA in APCs with ChIP at the IL-10 promoter and T-cell activation readouts

    PMID:19011628

    Open questions at the time
    • Whether repression depends on direct histone deacetylation at this locus not isolated from complex effects
    • Recruitment mechanism to IL-10 promoter unknown
  3. 2010 Medium

    Extended HDAC11 function to DNA replication licensing by linking it to the Cdt1/Geminin axis and re-replication control.

    Evidence Co-IP of HDAC11 with Cdt1/Geminin, ChIP at origins, chromatin decondensation and re-replication assays

    PMID:20980834

    Open questions at the time
    • Catalytic requirement for re-replication suppression not demonstrated
    • Single lab without in vivo confirmation
  4. 2017 High

    Demonstrated catalytic-activity-dependent transcriptional repression across tissues — of myogenic genes, of T-cell effector transcription factors Eomes/Tbet, and of CCL2 — cementing HDAC11 as a context-specific epigenetic repressor with immune and developmental roles.

    Evidence Active-site mutant in C2C12 myoblasts with promoter ChIP; KO and transgenic mice with ChIP at Eomes/Tbet and CCL2 promoters; EAE model

    PMID:28550044 PMID:28927261 PMID:30456376

    Open questions at the time
    • Direct histone substrate versus non-histone substrate contributions not separated
    • Mechanism of promoter recruitment differs across loci and is not unified
  5. 2018 High

    Connected HDAC11 to systemic metabolism, showing its catalytic activity suppresses the thermogenic/BAT program via BRD2 and that its loss protects against diet-induced obesity.

    Evidence KO mice with metabolic phenotyping, Co-IP establishing HDAC11-BRD2 interaction, UCP1 and AMPK pathway readouts

    PMID:29958910 PMID:30089714

    Open questions at the time
    • Molecular substrate of HDAC11 in the thermogenic program not yet identified at this stage
    • Role of BRD2 interaction in catalysis unresolved
  6. 2019 High

    Reframed HDAC11 enzymology by establishing lysine defatty-acylation as its dominant activity and identifying SHMT2 as a physiological substrate that controls type I IFN signaling.

    Evidence In vitro kinetic comparison of deacylase vs deacetylase activity, SILAC proteomics substrate ID, HDAC11 depletion in cells and mice with IFN readouts

    PMID:30819897

    Open questions at the time
    • Generality of defatty-acylation across the prior promoter functions not addressed
    • Full substrate repertoire unknown
  7. 2019 Medium

    Showed HDAC11 protein levels are set by ubiquitin-dependent turnover, with USP25 stabilizing HDAC11 and smoke-induced USP25 loss reducing HDAC11 to alter antibacterial defense.

    Evidence Co-IP of USP25 with HDAC11, CSE treatment and protein stability assays, bacterial load readout

    PMID:31746627

    Open questions at the time
    • Ubiquitination site on HDAC11 not mapped
    • Single lab Co-IP-based mechanism
  8. 2021 Medium

    Defined March1 as an E3 ligase degrading HDAC11 and placed HDAC11 in a KLF4 complex repressing OX40L, integrating turnover control with transcriptional output.

    Evidence Co-IP, ubiquitination assay, KLF4-HDAC11 complex detection and OX40L luciferase promoter assay

    PMID:34385821

    Open questions at the time
    • Ubiquitination site not defined
    • Direct versus indirect repression of OX40L not separated
  9. 2022 High

    Provided a mechanistic model for promoter targeting, showing STAT3 scaffolds HDAC11 to the Nos2 promoter to repress iNOS and antifungal killing.

    Evidence ChIP at Nos2, Co-IP with STAT3, KO mice, pharmacological inhibition (FT895), fungal killing assays

    PMID:36087429

    Open questions at the time
    • Whether STAT3 scaffolding generalizes to other repressed promoters unknown
  10. 2023 High

    Identified the molecular substrate underlying HDAC11's metabolic role, demonstrating demyristoylation of gravin-α/AKAP12 gates β-AR/UCP1 thermogenic signaling, and uncovered HSP90 K754 debutyrylation linking HDAC11 acyl-eraser activity to chemoresistance.

    Evidence Adipocyte-specific KO, FT895 inhibition, gravin-α myristoylation and PKA assays; butyrylome MS, in vitro deacylase assay and SDCBP-HDAC11 Co-IP for HSP90

    PMID:37460462 PMID:37607030

    Open questions at the time
    • Whether other acyl marks (butyrylation) are broadly erased by HDAC11 in vivo not established
  11. 2025 Medium

    Expanded the non-histone substrate repertoire through proteomics-based mutant trapping and site-specific assays, identifying BRAF K680, TPI1 K69, and Parkin K76 as substrates that couple HDAC11 to proliferation, fibrosis, and mitophagy.

    Evidence Proteomics mutant trapping, in vitro site-specific deacetylation, kinase/ubiquitination/mitophagy assays, KO mice and FT895 in fibrosis models

    PMID:41112094 PMID:41273269 PMID:41997918

    Open questions at the time
    • Most of 64 putative substrates remain unvalidated
    • Single-lab validations per substrate
  12. 2026 Medium

    Showed HDAC11 acts through the NuRD(MTA3) complex via its N-terminal region to repress TGFB1 and restrain HCC metastasis, defining a stable chromatin-modifying complex partner.

    Evidence MS, Co-IP and GST pull-down mapping the N-terminal interaction with MTA3, transcriptomics, in vivo metastasis rescue by TGFB1 knockdown

    PMID:41547814

    Open questions at the time
    • Catalytic requirement within the NuRD complex not isolated
    • Single lab

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved how HDAC11 selects between histone deacetylation and non-histone defatty-acylation in a given cellular context, and what determines its recruitment to specific promoters versus cytoplasmic/mitochondrial substrates.
  • No unifying model linking acyl-substrate preference to subcellular targeting
  • Recruitment determinants across diverse promoters not generalized
  • SF3B2/splicing role rests on a preprint

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 6 GO:0140110 transcription regulator activity 4 GO:0042393 histone binding 3 GO:0016787 hydrolase activity 2
Localization
GO:0000228 nuclear chromosome 3 GO:0005634 nucleus 1 GO:0005739 mitochondrion 1
Pathway
R-HSA-1430728 Metabolism 4 R-HSA-4839726 Chromatin organization 4 R-HSA-162582 Signal Transduction 3 R-HSA-168256 Immune System 3
Partners
BRD2E4BP4ERGHDAC6KLF4MTA3STAT3VDR
Complex memberships
NuRD(MTA3) complex

Evidence

Reading pass · 32 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2002 HDAC11 encodes a 347-residue, 39-kDa nuclear protein with histone deacetylase activity in vitro that is inhibited by trapoxin; epitope-tagged HDAC11 co-immunoprecipitates with HDAC6, indicating it resides in protein complexes containing HDAC6. In vitro deacetylase activity assay, trapoxin inhibition, Co-immunoprecipitation, nuclear localization by epitope-tag imaging The Journal of biological chemistry High 11948178
2008 HDAC11 negatively regulates IL-10 gene expression in antigen-presenting cells (APCs) by associating with the IL-10 promoter chromatin, thereby promoting inflammatory APC phenotype and suppressing immune tolerance. HDAC11 overexpression and siRNA knockdown in APCs, IL-10 expression assays, chromatin immunoprecipitation (ChIP) at the IL-10 promoter, T cell activation assays Nature immunology High 19011628
2014 HDAC6 (a cytoplasmic protein) and HDAC11 (a nuclear protein) are both recruited to the IL-10 gene promoter in APCs, but with divergent transcriptional effects: HDAC11 represses IL-10 while HDAC6 acts as a transcriptional activator; the two HDACs physically associate. ChIP showing co-recruitment of HDAC6 and HDAC11 to the IL-10 promoter, co-immunoprecipitation, siRNA knockdown of each HDAC Molecular immunology Medium 24747960
2019 HDAC11 functions as an efficient lysine defatty-acylase (>10,000-fold more efficient than its deacetylase activity) and defatty-acylates SHMT2 at a specific lysine residue; this modification does not affect SHMT2 enzymatic activity but regulates type I IFN receptor ubiquitination and cell-surface levels, thereby suppressing type I IFN signaling in cells and mice. In vitro biochemical deacylase assay, SILAC proteomics for substrate identification, biochemical validation of SHMT2 as substrate, HDAC11 depletion in cells and mice with IFN signaling readouts Proceedings of the National Academy of Sciences of the United States of America High 30819897
2019 HDAC11 represses HBV cccDNA transcription by deacetylating cccDNA-bound histone H3, specifically reducing H3K9ac and H3K27ac marks on cccDNA; this restricts HBV replication without affecting cccDNA production. ChIP assay on cccDNA-bound histones, HDAC11 overexpression/knockdown in HBV-transfected cells, HBV replication assays Antiviral research Medium 31600533
2010 HDAC11 binds Cdt1 (and does so more efficiently in the presence of Geminin) at replication origins during S-phase, inhibiting Cdt1-induced chromatin decondensation and MCM loading, thereby suppressing re-replication; this is counteracted by HBO1 HAT activity in G1. Co-immunoprecipitation of HDAC11 with Cdt1/Geminin, ChIP at replication origins, chromatin decondensation assays, re-replication assays Cell cycle (Georgetown, Tex.) Medium 20980834
2011 HDAC11 regulates OX40 ligand (OX40L) expression in Hodgkin lymphoma cells; siRNA-mediated depletion of HDAC11 upregulates OX40L surface expression, increases TNF-α and IL-17 production, and induces apoptosis. siRNA knockdown of HDAC11, flow cytometry for OX40L surface expression, cytokine measurement in supernatants Blood Medium 21239696
2013 HDAC11 binds the promoter region of the PAI-1 gene in a gender-specific manner (regulated by male hormone/testosterone/dihydrotestosterone); I/R injury or LPS causes HDAC11 to dissociate from the PAI-1 promoter, increasing local histone H3 acetylation and PAI-1 expression. ChIP assay showing HDAC11 binding to PAI-1 promoter, orchiectomy/DHT experiments, HDAC11 gene silencing with PAI-1 expression readout American journal of physiology. Renal physiology Medium 23657855
2017 HDAC11 is present at the Eomes and Tbet gene promoters in resting T cells (shown by ChIP) and dissociates upon T-cell activation; loss of HDAC11 increases Eomes and Tbet expression, enhancing T cell effector functions, cytokine production, and proliferation, while HDAC11 overexpression suppresses these genes. ChIP at Eomes/Tbet promoters, HDAC11 KO and transgenic overexpression mouse models, cytokine and transcription factor expression assays, in vivo GVHD model Blood High 28550044
2017 HDAC11 suppresses myoblast differentiation in a catalytic-activity-dependent manner; wild-type HDAC11 inhibits MyoD-dependent transcription of MEF2C and Myogenin by reducing histone acetylation near E-boxes at their promoters, whereas a catalytically inactive mutant (H142/143A) does not impede differentiation. Ectopic expression of WT and catalytically inactive HDAC11 mutant in C2C12 myoblasts, MyoD-dependent promoter activity assays (luciferase), histone acetylation ChIP at MEF2C and MYOG promoters Molecules and cells High 28927261
2017 HDAC11 controls CCL2 (MCP-1) gene expression by enabling binding of the transcription factor PU.1 to the CCL2 promoter; loss of HDAC11 reduces CCL2-driven monocyte/DC infiltration into the CNS and ameliorates EAE severity. HDAC11 KO mouse model, EAE (MS model), ChIP/promoter analysis of CCL2, immune cell infiltration analysis Life science alliance Medium 30456376
2018 HDAC11 catalytic activity suppresses the brown adipose tissue (BAT) transcriptional program through physical association with BRD2, a bromodomain acetyl-histone-binding protein; HDAC11 deletion in mice stimulates BAT formation, beiging of WAT, and enhances thermogenic potential. HDAC11 KO mouse model, ex vivo and cell-based assays showing HDAC11-BRD2 physical interaction (Co-IP), β-adrenergic receptor signaling assays, UCP1 expression readouts JCI insight High 30089714
2018 HDAC11 deficiency in mice confers resistance to high-fat diet-induced obesity; mechanistically, HDAC11 depletion boosts UCP1 expression and thermogenic capacity in BAT and activates the adiponectin-AdipoR-AMPK pathway in the liver. HDAC11 KO mouse model on HFD, metabolic phenotyping, UCP1 expression assays, AMPK pathway analysis EBioMedicine Medium 29958910
2018 HDAC11 forms a complex with E4BP4 transcription factor in cardiac CD4+ T cells and restricts E4BP4 binding to the IL-13 promoter, thereby repressing IL-13 transcription; reconstitution of HDAC11 in myocarditis T cells reduced IL-13 expression. Co-immunoprecipitation of HDAC11–E4BP4 complex, HDAC11 reconstitution and inhibition in patient-derived CD4+ T cells, IL-13 expression assays Journal of molecular and cellular cardiology Medium 30063898
2019 USP25 deubiquitinates HDAC11, stabilizing it; cigarette smoke extract (CSE) promotes USP25 ubiquitination and degradation, thereby reducing HDAC11 protein levels (without affecting HDAC11 transcript), increasing bacterial load; USP25–HDAC11 interaction demonstrated by Co-IP. Co-immunoprecipitation of USP25 and HDAC11, CSE treatment with protein stability assays, siRNA/OE of USP25, bacterial load assay American journal of physiology. Lung cellular and molecular physiology Medium 31746627
2020 HDAC11 inhibition in mouse oocytes (by specific inhibitor JB3-22) increases α-tubulin acetylation and H4K16 acetylation, disrupts spindle organization, causes chromosome misalignment, impairs kinetochore-microtubule attachment and spindle assembly checkpoint, thereby blocking meiotic progression. HDAC11-specific inhibitor (JB3-22) treatment of mouse oocytes, immunofluorescence for spindle/chromosome/kinetochore markers, acetylation level measurement Cell cycle (Georgetown, Tex.) Medium 31910069
2020 HDAC11 depletion in HCC increases histone acetylation at the LKB1 promoter, activating LKB1 transcription and thus the AMPK signaling pathway, which inhibits glycolysis and suppresses cancer stemness; conditional HDAC11 KO mice showed reduced hepatocellular tumorigenesis. Conditional KO mouse model, ChIP at LKB1 promoter, AMPK/glycolysis pathway analysis, stemness assays Cancer research Medium 33602787
2020 HDAC11 is localized in skeletal muscle mitochondria; its genetic deficiency enhances mitochondrial fatty acid β-oxidation through activating the AMPK-acetyl-CoA carboxylase pathway, reduces acylcarnitine levels, increases oxidative myofibers, and improves muscle fatigue resistance and strength. HDAC11 KO mouse model, mitochondrial fractionation/localization by imaging, AMPK-ACC pathway assays, metabolomics (acylcarnitines), fiber-type analysis The FEBS journal Medium 32563202
2021 HDAC11 forms a complex with ERG and decreases ERG acetylation levels; HDAC11 knockdown mitigates TNF-α-induced pyroptosis via suppression of both NLRP3/caspase-1/GSDMD and caspase-3/GSDME pathways in vascular endothelial cells. Co-immunoprecipitation of HDAC11 with ERG, acetylation assays of ERG, siRNA knockdown of HDAC11/GSDME in HUVECs, pyroptosis markers (caspase-1, caspase-3, GSDMD, GSDME, LDH, PI staining) Cell death discovery Medium 35279683
2021 HDAC11 is recruited to the C/EBPβ gene promoter in MDSCs (shown by ChIP); loss of HDAC11 upregulates C/EBPβ, leading to elevated arginase activity and NO production that enhance MDSC suppressive function. ChIP showing HDAC11 at C/EBPβ promoter in WT MDSCs, HDAC11 KO mouse-derived MDSCs, arginase activity and iNOS/NO assays Journal of leukocyte biology Medium 33866588
2021 March1 (an E3 ubiquitin ligase) directly ubiquitinates HDAC11, promoting its degradation; HDAC11 forms a complex with transcription factor KLF4 to repress OX40L gene promoter activity; loss of HDAC11 (via March1-induced degradation) de-represses OX40L expression. Co-immunoprecipitation, immunofluorescence co-localization, luciferase promoter assay, ubiquitination assay, KLF4–HDAC11 complex detection Journal of asthma and allergy Medium 34385821
2022 HDAC11 negatively regulates Nos2 (iNOS) expression in macrophages through its association with STAT3 (which acts as a scaffold protein anchoring HDAC11 to the Nos2 promoter); HDAC11 deficiency increases H3/H4 acetylation at the Nos2 promoter, boosting iNOS and NO-mediated antifungal killing. ChIP at Nos2 promoter, Co-IP of HDAC11 with STAT3, HDAC11 KO mouse model, fungal killing assays, HDAC11 inhibitor (FT895) in mouse and human cells Redox biology High 36087429
2023 HDAC11 acts as the eraser of lysine butyrylation (Kbu) on HSP90 at K754; KAT8 is the writer of this modification; SDCBP increases Kbu on HSP90 by competitively binding to HDAC11, preventing its eraser activity, leading to HSP90 overexpression and chemoresistance. Butyrylome profiling MS, gain/loss-of-function experiments, in vitro deacylase assays identifying HDAC11 as Kbu eraser for HSP90 K754, Co-IP of SDCBP–HDAC11 Cell discovery Medium 37460462
2023 HDAC11 demyristoylates gravin-α (AKAP12); HDAC11 inhibition preserves gravin-α myristoylation, enabling β-adrenergic receptor signaling that induces UCP1 expression via a biphasic mechanism: an acute PKA-independent post-transcriptional response and a delayed PKA-dependent transcriptional response; adipocyte-specific HDAC11 deletion robustly induces UCP1 in adipose tissue and elevates body temperature. Adipocyte-specific HDAC11 KO mice, HDAC11-selective inhibitor FT895 in vivo and ex vivo (human AT), gravin-α myristoylation assays, UCP1 expression (protein/mRNA), PKA activity assays The Journal of clinical investigation High 37607030
2017 HDAC11 is synaptic-enriched (not exclusively nuclear/cytoplasmic as previously reported) in brain tissue; in HDAC11 KO mice, loss of HDAC11 selectively decreases Fez1 expression in the hippocampus in an age-dependent and brain-region-specific manner. Subcellular fractionation showing synaptic enrichment, HDAC11 KO mouse brain analysis, Fez1 expression in cortical/cerebellar/hippocampal regions Scientific reports Medium 28928414
2017 VDR (vitamin D receptor) forms a complex with HDAC11 in intestinal epithelial cells under VitD-sufficient conditions; in VitD-deficient conditions, HDAC11 binding to tight junction protein promoters increases, repressing their transcription and impairing barrier function; calcitriol abolishes this repressive HDAC11 promoter binding. Co-immunoprecipitation of VDR–HDAC11, ChIP at tight junction protein promoters, calcitriol treatment, epithelial barrier function assays Oncotarget Medium 28938596
2025 HDAC11 deacetylates BRAF at K680, suppressing BRAF kinase activity and reducing cell proliferation; proteomics-based mutant trapping identified BRAF among 64 putative HDAC11 substrates. Proteomics mutant trapping to identify substrates, biochemical deacetylation assay of BRAF K680, kinase activity assay, cell proliferation assay ACS chemical biology Medium 41273269
2025 HDAC11 deacetylates TPI1 (triosephosphate isomerase 1) at K69, stabilizing TPI1 by attenuating K48-linked polyubiquitination; this stabilization promotes fibroblast-to-myofibroblast differentiation, proliferation, and migration in pulmonary fibrosis; TGF-β1 enhances this HDAC11-mediated deacetylation. In vitro deacetylation assay, site-specific mutagenesis (K69), ubiquitination assay, TGF-β1 stimulation in fibroblasts, KO mice and HDAC11 inhibitor (FT895) in bleomycin fibrosis model Research (Washington, D.C.) Medium 41112094
2025 HDAC11 deacetylates Parkin at K76, promoting Parkin ubiquitination and degradation; this impairs mitophagy and drives pro-fibrotic M2 macrophage polarization and macrophage-myofibroblast transition in idiopathic pulmonary fibrosis; adoptive transfer of HDAC11-deficient macrophages attenuates fibrosis. Site-specific deacetylation assay (Parkin K76), ubiquitination assay, HDAC11 KO mouse and macrophage adoptive transfer, mitophagy assays, fibrosis histology Nature communications Medium 41997918
2026 HDAC11 interacts with the NuRD (MTA3) complex through its N-terminal region; this complex transcriptionally represses TGFB1, thereby inhibiting HCC metastasis; HDAC11 silencing increases TGFB1 expression and metastatic potential, which is reversed by concurrent TGFB1 knockdown. Mass spectrometry identifying HDAC11-NuRD(MTA3) interaction, Co-IP and GST pull-down of HDAC11 N-terminal region with MTA3, transcriptomic analysis, in vitro and in vivo metastasis assays Clinical epigenetics Medium 41547814
2026 HDAC11 regulates RNA splicing via de-fatty acylation (de-myristoylation) of the spliceosomal protein SF3B2 at K10; a de-myristoylation mimetic mutant (K10R) exhibits altered pre-mRNA binding and promotes alternative splicing toward the AR-v7 variant in HCC cells in a cell-type-specific manner. Metabolic labeling, mass spectrometry, click chemistry, in vitro deacylase assay establishing SF3B2 K10 as direct HDAC11 substrate, SF3B2 K10R mutagenesis, AR splicing isoform analysis by RT-PCR, HDAC11 OE/KD bioRxiv : the preprint server for biologypreprint Medium 42124652
2025 FGL2 (neutrophil-derived fibrinogen-like protein 2) interacts with HDAC11 in neutrophils, promoting histone H3 deacetylation and facilitating PAD4-mediated citrullination to drive NETs release and immunothrombosis in MASLD liver fibrosis. Co-immunoprecipitation of FGL2-HDAC11, histone H3 acetylation assays, PAD4 citrullination assays, FGL2 genetic disruption and NETs inhibition mouse models Advanced science (Weinheim, Baden-Wurttemberg, Germany) Low 42107082

Source papers

Stage 0 corpus · 93 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2002 Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. The Journal of biological chemistry 566 11948178
2008 The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nature immunology 369 19011628
2019 HDAC11 regulates type I interferon signaling through defatty-acylation of SHMT2. Proceedings of the National Academy of Sciences of the United States of America 151 30819897
2021 HDAC11 Regulates Glycolysis through the LKB1/AMPK Signaling Pathway to Maintain Hepatocellular Carcinoma Stemness. Cancer research 139 33602787
2022 HDAC11 promotes both NLRP3/caspase-1/GSDMD and caspase-3/GSDME pathways causing pyroptosis via ERG in vascular endothelial cells. Cell death discovery 133 35279683
2014 Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells. Molecular immunology 113 24747960
2018 Programming and Regulation of Metabolic Homeostasis by HDAC11. EBioMedicine 98 29958910
2011 HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. Blood 96 21239696
2020 HDAC11: a rising star in epigenetics. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 92 32841898
2012 HDAC11 is a novel drug target in carcinomas. International journal of cancer 91 23024001
2018 HDAC11 suppresses the thermogenic program of adipose tissue via BRD2. JCI insight 90 30089714
2017 HDAC11 is a regulator of diverse immune functions. Biochimica et biophysica acta. Gene regulatory mechanisms 85 29222071
2020 Novel HDAC11 inhibitors suppress lung adenocarcinoma stem cell self-renewal and overcome drug resistance by suppressing Sox2. Scientific reports 76 32170113
2017 Alcohol-induced miR-155 and HDAC11 inhibit negative regulators of the TLR4 pathway and lead to increased LPS responsiveness of Kupffer cells in alcoholic liver disease. Journal of leukocyte biology 72 28584078
2021 HDAC11: a multifaceted histone deacetylase with proficient fatty deacylase activity and its roles in physiological processes. The FEBS journal 62 33891374
2017 T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model. Blood 59 28550044
2010 Chromatin unfolding by Cdt1 regulates MCM loading via opposing functions of HBO1 and HDAC11-geminin. Cell cycle (Georgetown, Tex.) 57 20980834
2017 Essential role for histone deacetylase 11 (HDAC11) in neutrophil biology. Journal of leukocyte biology 53 28550123
2017 Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival. Cell death & disease 48 28252645
2013 Gender-specific role of HDAC11 in kidney ischemia- and reperfusion-induced PAI-1 expression and injury. American journal of physiology. Renal physiology 47 23657855
2020 HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms. Blood 45 31750881
2022 HDAC11, an emerging therapeutic target for metabolic disorders. Frontiers in endocrinology 44 36339432
2019 HDAC11 restricts HBV replication through epigenetic repression of cccDNA transcription. Antiviral research 44 31600533
2020 Promoter Hypomethylation and miR-145-5p Downregulation- Mediated HDAC11 Overexpression Promotes Sorafenib Resistance and Metastasis of Hepatocellular Carcinoma Cells. Frontiers in cell and developmental biology 42 32903337
2018 Loss of HDAC11 ameliorates clinical symptoms in a multiple sclerosis mouse model. Life science alliance 36 30456376
2017 HDAC11 Inhibits Myoblast Differentiation through Repression of MyoD-Dependent Transcription. Molecules and cells 35 28927261
2020 HDAC11 is a novel regulator of fatty acid oxidative metabolism in skeletal muscle. The FEBS journal 33 32563202
2019 Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors. ACS omega 30 31788622
2020 Loss of HDAC11 accelerates skeletal muscle regeneration in mice. The FEBS journal 28 32602219
2021 Hydroxytyrosol Acetate Inhibits Vascular Endothelial Cell Pyroptosis via the HDAC11 Signaling Pathway in Atherosclerosis. Frontiers in pharmacology 26 33967800
2020 HDAC11 promotes meiotic apparatus assembly during mouse oocyte maturation via decreasing H4K16 and α-tubulin acetylation. Cell cycle (Georgetown, Tex.) 26 31910069
2020 Long non‑coding RNA BCYRN1 promotes prostate cancer progression via elevation of HDAC11. Oncology reports 26 32705287
2020 LncRNA ST8SIA6-AS1 promotes hepatocellular carcinoma cell proliferation and resistance to apoptosis by targeting miR-4656/HDAC11 axis. Cancer cell international 25 32536820
2018 The Class IV human deacetylase, HDAC11, exhibits anti-influenza A virus properties via its involvement in host innate antiviral response. Cellular microbiology 24 30511515
2017 Vitamin D3 induces vitamin D receptor and HDAC11 binding to relieve the promoter of the tight junction proteins. Oncotarget 24 28938596
2023 Trapoxin A Analogue as a Selective Nanomolar Inhibitor of HDAC11. ACS chemical biology 21 36977486
2023 Lysine butyrylation of HSP90 regulated by KAT8 and HDAC11 confers chemoresistance. Cell discovery 21 37460462
2023 HDAC11: A novel target for improved cancer therapy. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 21 37659201
2019 Cigarette smoke extract modulates Pseudomonas aeruginosa bacterial load via USP25/HDAC11 axis in lung epithelial cells. American journal of physiology. Lung cellular and molecular physiology 20 31746627
2023 Development and Pharmacochemical Characterization Discover a Novel Brain-Permeable HDAC11-Selective Inhibitor with Therapeutic Potential by Regulating Neuroinflammation in Mice. Journal of medicinal chemistry 19 37972387
2017 Disruption to schizophrenia-associated gene Fez1 in the hippocampus of HDAC11 knockout mice. Scientific reports 19 28928414
2007 Mutational analyses of WNT7A and HDAC11 as candidate tumour suppressor genes in sporadic malignant pancreatic endocrine tumours. Clinical endocrinology 19 17201809
2018 Clinicopathological features and prediction values of HDAC1, HDAC2, HDAC3, and HDAC11 in classical Hodgkin lymphoma. Anti-cancer drugs 17 29481474
2018 HDAC11 regulates interleukin-13 expression in CD4+ T cells in the heart. Journal of molecular and cellular cardiology 16 30063898
2013 Proliferative status regulates HDAC11 mRNA abundance in nontransformed fibroblasts. Cell cycle (Georgetown, Tex.) 16 24047695
2022 A novel HDAC11 inhibitor potentiates the tumoricidal effects of cordycepin against malignant peripheral nerve sheath tumor through the Hippo signaling pathway. American journal of cancer research 15 35261809
2021 The role of HDAC11 in obesity-related metabolic disorders: A critical review. Journal of cellular physiology 15 33481312
2021 HDAC11 inhibition disrupts porcine oocyte meiosis via regulating α-tubulin acetylation and histone modifications. Aging 15 33742608
2023 HDAC11 inhibition triggers bimodal thermogenic pathways to circumvent adipocyte catecholamine resistance. The Journal of clinical investigation 14 37607030
2024 shRNA-mediated gene silencing of HDAC11 empowers CAR-T cells against prostate cancer. Frontiers in immunology 13 38835760
2022 HDAC11 negatively regulates antifungal immunity by inhibiting Nos2 expression via binding with transcriptional repressor STAT3. Redox biology 13 36087429
2025 Staphylococcus aureus induces mitophagy via the HDAC11/IL10 pathway to sustain intracellular survival. Journal of translational medicine 12 39905391
2022 HDAC11 Regulates the Proliferation of Bovine Muscle Stem Cells through the Notch Signaling Pathway and Inhibits Muscle Regeneration. Journal of agricultural and food chemistry 12 35837734
2022 LncRNA C9orf139 can regulate the progression of esophageal squamous carcinoma by mediating the miR-661/HDAC11 axis. Translational oncology 12 35917643
2021 HDAC11 regulates expression of C/EBPβ and immunosuppressive molecules in myeloid-derived suppressor cells. Journal of leukocyte biology 11 33866588
2021 Antitumor activity of novel POLA1-HDAC11 dual inhibitors. European journal of medicinal chemistry 11 34772529
2024 Utilization of an optimized AlphaFold protein model for structure-based design of a selective HDAC11 inhibitor with anti-neuroblastoma activity. Archiv der Pharmazie 10 38996352
2019 Probiotics ingestion prevents HDAC11-induced DEC205+ dendritic cell dysfunction in night shift nurses. Scientific reports 10 31784669
2016 Functional Analysis of Histone Deacetylase 11 (HDAC11). Methods in molecular biology (Clifton, N.J.) 10 27246214
2025 HDAC11 Inhibition as a Potential Therapeutic Strategy for AML: Target Identification, Lead Discovery, Antitumor Potency, and Mechanism Investigation. Journal of medicinal chemistry 9 40177883
2022 HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma. Cancer gene therapy 9 35332245
2022 LncRNA HDAC11-AS1 Suppresses Atherosclerosis by Inhibiting HDAC11-Mediated Adropin Histone Deacetylation. Journal of cardiovascular translational research 9 35505157
2021 E3 Ubiquitin Ligase March1 Facilitates OX40L Expression in Allergen-Stimulated Dendritic Cells Through Mediating the Ubiquitination of HDAC11. Journal of asthma and allergy 9 34385821
2023 HDAC11 deficiency resists obesity by converting adipose-derived stem cells into brown adipocyte-like cells. International journal of biological macromolecules 8 38110164
2022 Long Noncoding RNA TFAP2A-AS1 Suppressed Hepatitis B Virus Replication by Modulating miR-933/HDAC11. Disease markers 6 35478990
2017 Stabilizing HDAC11 with SAHA to assay slow-binding benzamide inhibitors. Bioorganic & medicinal chemistry letters 6 28501514
2023 Targeting HDAC11 activity by FT895 restricts EV71 replication. Virus research 4 37024058
2023 HDAC11 mediates the ubiquitin-dependent degradation of p53 and inhibits the anti-leukemia effect of PD0166285. Medical oncology (Northwood, London, England) 4 37805625
2024 HDAC11 Regulates Palmitate-induced NLRP3 Inflammasome Activation by Inducing YAP Expression in THP-1 Cells and PBMCs. Endocrinology 3 38366363
2024 [Progress on the involvement of HDAC11 in the regulation of mammalian oocyte maturation and early embryonic development]. Sheng li xue bao : [Acta physiologica Sinica] 3 38939938
2025 In silico screening of a designed focused chemical space identifies novel alkyl hydrazides as potent HDAC11 inhibitors. Computers in biology and medicine 2 40617084
2025 HDAC11-Mediated Deacetylation of Triosephosphate Isomerase 1 Promotes Idiopathic Pulmonary Fibrosis. Research (Washington, D.C.) 2 41112094
2024 Emerging role of HDAC11 in skeletal muscle biology. Frontiers in cell and developmental biology 2 38859964
2023 A novel chimeric RNA originating from BmCPV S4 and Bombyx mori HDAC11 transcripts regulates virus proliferation. PLoS pathogens 2 38048361
2025 WITHDRAWN: Overexpression of NR4A2 Alleviates Renal and Myocardial Injury in Diabetic Nephropathy in Rats Through the HDAC11/ SPRY1 Pathway. Endocrine, metabolic & immune disorders drug targets 1 36281860
2025 HDAC11 in ovarian granulosa cells coordinates LH in the maturation of oocytes in Tan sheep. Acta biochimica et biophysica Sinica 1 40065721
2025 Identification of Critical Molecular Pathways Induced by HDAC11 Overexpression in Cardiac Mesenchymal Stem Cells. Biomolecules 1 40427555
2025 The role of HDAC11 in age-related hearing loss: Mechanisms and therapeutic implications. Open life sciences 1 40667486
2025 HDAC11 promotes renal fibrosis by induing partial epithelial-mesenchymal transition and G2/M phase arrest in renal epithelial cells. Molecular medicine (Cambridge, Mass.) 1 41275091
2026 HDAC11 interacts with the NuRD (MTA3) complex to transcriptionally suppress TGFβ1 expression and inhibit hepatocellular carcinoma metastasis. Clinical epigenetics 0 41547814
2026 Epigenetic regulation by HDAC11-driven STAT3 activation promotes pro-inflammatory cytokine production and endothelial dysfunction upon bacterial infection in diabetes. Cell communication and signaling : CCS 0 41668160
2026 Discovery of a Hydroxamic Acid-Based HDAC11 Isoform-Selective Inhibitor with Oral Anti-AML Potency. Journal of medicinal chemistry 0 41787751
2026 Hdac11 promotes idiopathic pulmonary fibrosis through macrophage M2-type polarization and myofibroblast accumulation by inhibiting Parkin-dependent mitophagy. Nature communications 0 41997918
2026 FGL2-HDAC11 Drives Immunothrombosis via NETs-Mediated Endothelial Capillarization in MASLD Fibrosis. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 0 42107082
2026 HDAC11 Regulates RNA Splicing via De-Fatty Acylation of SF3B2. bioRxiv : the preprint server for biology 0 42124652
2026 Super-enhancer-associated lncRNA HDAC11-AS1 aggravates hepatocellular carcinoma progression by modulating HDAC11 and NUP210 expression via promoting super-enhancer activity. Cellular oncology (Dordrecht, Netherlands) 0 42126774
2025 HDAC11 deficiency regulates age-related muscle decline and sarcopenia. GeroScience 0 40220154
2025 HDAC11 promotes renal fibrosis by induing partial epithelial-mesenchymal transition and G2/M phase arrest in renal epithelial cells. Research square 0 40386380
2025 HDAC11 Deacetylates BRAF to Regulate Kinase Activity and Cell Proliferation. ACS chemical biology 0 41273269
2025 HDAC11 deficiency improves muscle phenotype in a Duchenne muscular dystrophy murine model by reducing inflammation and fibrosis. Life sciences 0 41407152
2023 HDAC11 inhibition triggers bimodal thermogenic pathways to circumvent adipocyte catecholamine resistance. bioRxiv : the preprint server for biology 0 37034582
2023 Identification of potential HDAC11 deacylase substrates by affinity pulldown MS. Methods in enzymology 0 37245910
2023 Retracted: Long Noncoding RNA TFAP2A-AS1 Suppressed Hepatitis B Virus Replication by Modulating miR-933/HDAC11. Disease markers 0 37387751

Missed literature

Know a paper Affinage missed for HDAC11? Flag it for the maintainers and the community.

No submissions yet.